Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiovascular Diagnostics files for monitoring tests:

This article was originally published in Clinica

Executive Summary

Cardiovascular Diagnostics is seeking US clearance for two tests to monitor the effects of anti-clotting drugs. The Ecarin clotting time test is designed to monitor the effects of the thrombin inhibitor PEG-Hirudin, made by German pharmaceutical company Knoll. The low range heparin management test measures heparin levels in the ranges needed during cardiac catheterisation. Both tests are based on the company's Thrombolytic Assessment System, a dry chemistry technology platform from which it has developed a range of therapeutic diagnostics for angina, heart attack, stroke and deep vein thrombosis and pulmonary and arterial emboli.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT080598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel